ABLYNX ANNOUNCES 2016 HALF-YEAR RESULTS AND YEAR-TO-DATE BUSINESS UPDATE - Seite 2

"We continued to make good progress in our most advanced clinical programme, where we are developing caplacizumab for the treatment of acquired TTP, and are on track to file the dossier for conditional approval in Europe early next year. Recruitment for the HERCULES Phase III trial with caplacizumab in acquired TTP patients is proceeding well and we now intend to increase the power of the key secondary efficacy endpoint by recruiting about 40% more patients than originally planned while still aiming to meet our original goal to report the study results before the end of 2017."

"Our R&D pipeline is developing very encouragingly and now includes more than 45 proprietary and partnered programmes. Three new programmes entered clinical development with our partners and >15 new wholly-owned and partnered discovery programmes have been initiated since the beginning of the year, demonstrating our commitment to continue to fuel our product pipeline."

"In June, we further strengthened our cash position through a €74.2 million (gross) oversubscribed private placement of new shares with existing and new investors, and we remain focused on delivering sustainable value to all our stakeholders."

Financial review - 1 January 2016 to 30 June 2016

Key figures

(€ million)		First six months 2016	First six months 2015	% change
Total revenue and grant income		53.5	38.4	39%
	R&D income	53.1	38.0	40%
	Grants	0.4	0.4	-
Operating expenses		(55.5)	(45.9)	21%
	R&D	(49.0)	(40.3)	22%
	G&A	(6.5)	(5.6)	16%
Operating result		(2.0)	(7.4)	73%
Net financial result		24.9	(7.7)	>100%
Net result		22.8	(15.2)	>100%
Net operational cash flow		(19.0) (1)	(35.1) (2)	46%
Cash at 30 June*		288.7 (3)	268.4 (4)	8%